Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Revolution Medicines, Inc.

Get SEC filing alerts via email and in your feed for Revolution Medicines, Inc.

RVMD RVMDW

Revolution Medicines, Inc.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage biotech focused on developing targeted therapies for RAS-driven cancers. Utilizing proprietary tri-complex technology, it creates small molecules to inhibit active RAS proteins, addressing unmet needs in oncology. Its pipeline includes novel RAS(ON) inhibitors for various mutations, aiming to improve treatment durability and efficacy across multiple tumor types, with plans for pivotal trials and potential commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Revolution Medicines, Inc.

1
1
Revolution Medicines, Inc. Revolution Medicines Reports $453.8 Million Net Loss in Q1 2026 Amid Increased R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Revolution Medicines, Inc. Revolution Medicines Reports $1.13 Billion Net Loss for 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Revolution Medicines, Inc. Revolution Medicines Reports $305.2M Net Loss and Increased R&D Expenses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Revolution Medicines, Inc. Revolution Medicines Reports $247.8 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Revolution Medicines, Inc. Revolution Medicines Reports $213.4 Million Net Loss in Q1 2025, Up 84% Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Revolution Medicines, Inc. Revolution Medicines Reports Significant Revenue Decline, Increased Expenses, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments